Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 study of CCX168 in IgA nephropathy on RAAS blockade
2014-003402-33Phase 2Completed
- Sponsor
- ChemoCentryx
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avacopan in IgA nephropathy (IgAN), sponsored by ChemoCentryx. Started Dec 2014; status: completed.
02
Drugs
avacopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2014-003402-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003402-33.